Evommune gains after eczema drug meets mid-stage trial goal
BUZZ-Evommune gains after eczema drug meets mid-stage trial goal ** Shares of drug developer Evommune EVMN.N rise 4.9% to $8.67 premarket
** Co says its experimental injectable drug EVO301 met the main goal of a mid-stage trial involving 70 adults with moderate-to-severe atopic dermatitis, commonly known as eczema
** Says patients treated with EVO301 had a 55% average reduction in the severity and extent of eczema after 12 weeks, compared with 22% for those given placebo
** About 29% of EVO301 patients achieved at least a 75% improvement in eczema severity versus 9% on placebo
** Drug was given twice during the trial, at the start and after four weeks; effects continued to improve for eight weeks after the final dose
** Treatment-related side effects were reported in 10.4% of EVO301 patients versus 13.6% on placebo; no treatment-related serious or severe side effects were reported
** As of last close, EVMN down 51.8% YTD
(Reporting by Kunal Das in Bengaluru)